A Prospective, Non-randomized, Sequentially-enrolled, Multi-center, Phase II Study to Evaluate the SENSE Device's Ability to Detect Traumatic Brain Injury

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

The study population will consist of 3 mutually-exclusive sets of patients and subjects: * TBI patients with intracranial bleeding * TBI patients without intracranial bleeding * Control subjects with normal brain health. Research subjects ages 22 and older will be enrolled. All TBI patients must be monitored with the SENSE Device within 6 hours of a diagnostic head CT scan ordered by a treating clinician and within 24 hours of injury.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Healthy Volunteers: t
View:

• • Male or female adults age 22 and older

‣ Patients with TBI who have a head CT scan obtained in the mobile stroke unit, emergency department, or hospital, ordered by a treating clinician OR control subjects with normal brain health.

⁃ For patients with traumatic intracranial hemorrhage, blood is visible on ≥ 3 consecutive axial CT slices.

⁃ Signed written informed consent by study subject or, if subject is unable, by subject's next of kin or legally authorized representative.

⁃ Willingness and ability to comply with schedule for study procedures.

Locations
United States
Florida
University of Florida
RECRUITING
Gainesville
Ohio
University of Cincinnati
RECRUITING
Cincinnati
Pennsylvania
University of Pittsburgh
RECRUITING
Pittsburgh
South Carolina
MUSC
RECRUITING
Charleston
Texas
UT Houston
RECRUITING
Houston
UTSA
RECRUITING
San Antonio
Contact Information
Primary
Sara M Keegan, MEd
skeegan@senseneuro.com
5133098325
Time Frame
Start Date: 2025-07-11
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 150
Treatments
TBI patients with intracranial bleeding
50 patients with TBI with intracranial bleeding
TBI patients without intracranial bleeding
50 patients with TBI without intracranial bleeding
Control subjects with normal brain health
50 control subjects with normal brain health
Related Therapeutic Areas
Sponsors
Collaborators: Congressionally Directed Medical Research Programs
Leads: Sense Diagnostics, LLC

This content was sourced from clinicaltrials.gov